Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 8;205(6):223.
doi: 10.1007/s00203-023-03574-0.

Impact of the first-line antiretroviral therapy on soluble markers of inflammation in cohort of human immunodeficiency virus type 1 in Moroccan patients: a prospective study

Affiliations

Impact of the first-line antiretroviral therapy on soluble markers of inflammation in cohort of human immunodeficiency virus type 1 in Moroccan patients: a prospective study

Asmaa Haddaji et al. Arch Microbiol. .

Abstract

Chronic inflammation and immune activation are a hallmark of HIV-1 infection. In this study, we assessed inflammation biomarkers in a cohort of people living with HIV-1 (PLWH) before and after long-term suppressive combined antiretroviral therapy (cART). A single-center prospective cohort study was conducted to assess inflammatory biomarkers in 86 cART-naive PLWH and after receiving suppressive cART and 50 uninfected controls. Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and soluble CD14 (sCD14) were measured using enzyme-linked immunosorbent assay (ELISA). No significant difference was found in IL-6 levels between cART-naïve PLWH and controls (p = 0.753). In contrast, TNF-α level showed a significant difference between cART naïve-PLWH and controls (p = 0.019). Interestingly, IL-6 and TNF-α levels were significantly decreased in PLWH after cART (p < 0.0001). The sCD14 showed no significant difference between cART-naïve patients and controls (p = 0.839) and similar levels were observed in pre- and post-treatment (p = 0.719). Our results highlight the critical importance of early treatment to reduce inflammation and its consequences during HIV infection.

Keywords: AIDS; Antiretroviral therapy; HIV; IL-6; TNF-α; sCD14.

PubMed Disclaimer

Similar articles

References

    1. Ananworanich J, Sacdalan CP, Pinyakorn S et al (2016) Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Erad 2:43–48 - DOI - PubMed - PMC
    1. Baker JV, Neuhaus J, Duprez D et al (2011) Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 56:36–43. https://doi.org/10.1097/QAI.0b013e3181f7f61a - DOI - PubMed - PMC
    1. Baker JV, Sharma S, Grund B et al (2017) Systemic inflammation, coagulation, and clinical risk in the START trial. Open Forum Infect Dis 21:770. https://doi.org/10.1186/s13063-020-04678-4 - DOI
    1. Beignon A-S (2005) Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor- viral RNA interactions. J Clin Investig 115:3265–3275. https://doi.org/10.1172/JCI26032 - DOI - PubMed - PMC
    1. Borges ÁH, Silverberg MJ, Wentworth D et al (2013) Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 27:1433–1441. https://doi.org/10.1097/QAD.0b013e32835f6b0c - DOI - PubMed

LinkOut - more resources